Stock Ratings / Health Care / AKTX / options

KYNB (32) COCP (35) PBM (46) AEON (48) ⌘ Pro Terminal →

Akari Therapeutics plc ADS (AKTX) Options Positioning, Max Pain & Unusual Sweeps

$8.24 +3.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.27

Akari Therapeutics plc ADS (AKTX) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $18.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AKTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AKTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Akari Therapeutics plc ADS (NASDAQ: AKTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $8.24 (+3.00% 1D, market cap $18.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AKTX ranks #620 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AKTX compare to KYNB and COCP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AKTX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M) and COCP (Cocrystal Pharma Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $18.9M). Among the 5-stock peer group, AKTX leads on earnings multiple (N/A) while AKTX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AKTX?

▼

Per AKTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001541157), Akari Therapeutics plc ADS generated $0 in revenue, -$17.3M in net income, and -$10.6M in free cash flow against $47.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.27 (+0.35%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AKTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY AKTX SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (24% of score)

FRED Regime × Technicals: 17% of 52W Range • RSI-14 at 45.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$8.54+15.8% Next Q

Q2 (-2Q)

Grade D$9.89-22.9% Next Q

Q3 (-1Q)

Grade D$7.63+8% Next Q

Current

Grade D-$8.24-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AKTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AKTX currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.29) and Max Pain ($8.65) forces dealer call-delta covering toward $35.28.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AKTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AKTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (AKTX)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for AKTX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AKTX)

✓Walkthrough of AKTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AKTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +37.56%⚡ TESTING RESISTANCE

2026-11-02O $9.20H $9.20L $8.00C $8.24VOL 97.0K

RES: $9.25SUP: $7.14SMA50: $9.29SMA200: $9.05

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AKTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AKTX Butterfly Map → + Track AKTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AKTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AKTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AKTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AKTX)

Health Care Rank #620 of 1016 ⚔️ KYNB vs AKTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AKTX vs. KYNB, COCP, PBM, AEON)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Akari Therapeutics plc ADS (AKTX) ranks #620 by composite RQD confidence (37/100, grade D-) and #840 by equity capitalization ($18.3M). Within this direct 5-issuer industry benchmark cohort, AKTX leads on earnings valuation at N/A trailing P/E, while AKTX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. AEON currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with AKTX at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AKTX ACTIVE Akari Therapeutics plc ADS	D-	37/100	—	—	-35.0%	+3.00%	$18.3M	Benchmark Subject
KYNB Kyntra Bio Inc.	E	32/100	—	91.4%	-35.0%	-1.72%	$18.8M	/kynb-vs-aktx →
COCP Cocrystal Pharma Inc.	D-	35/100	—	—	-35.0%	+1.53%	$18.9M	/cocp-vs-aktx →
PBM Psyence Biomedical Ltd.	D	46/100	—	—	—	-8.31%	$19.2M	/pbm-vs-aktx →
AEON AEON Biopharma Inc. (Class A)	D	48/100	—	—	-35.0%	-6.80%	$17.4M	/aeon-vs-aktx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001541157

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Akari Therapeutics plc ADS (AKTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$17.3M, operating cash flow of -$10.6M, and free cash flow of -$10.6M (+15.8% YoY). On the balance sheet, AKTX closed FY2025 with $47.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$17.3M	-$10.6M	-$10.6M	$47.9M	—
FY2024 (FY)	2024-12-31	$0	-$19.8M	-$12.6M	-$12.6M	$50.6M	—
FY2023 (FY)	2023-12-31	$367.9K	-$10.0M	-$16.4M	-$16.4M	—	—

3. AKTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AKTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AKTX compare to KYNB and COCP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AKTX?

Where is AKTX trading relative to its 50-day, 200-day, and 52-week technical levels?

AKTX last traded at $8.24 (+3.00% on volume of 45,801 shares), positioning the stock -11.30% below its 50-day simple moving average ($9.29) and -8.95% below its 200-day simple moving average ($9.05). Across its 52-week range of $3.02 to $33.60, AKTX sits at the 17.1% percentile with a 14-day RSI of 45.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.21 to $9.27).

AKTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is AKTX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for AKTX.

Direct Sub-Reports: AKTX RQD Cockpit AKTX 12M Forecast AKTX Earnings & Move AKTX Dividends & DRIP AKTX Insiders & 13F AKTX Whale Options AKTX Profit Sankey AKTX News & Why